Neurocrine Biosciences, Inc. (NBIX)
136.21
-1.16
(-0.84%)
USD |
NASDAQ |
Jan 23, 16:00
136.09
-0.12
(-0.09%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (TTM): 936.90M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc. | 10.13B |
| Masimo Corp. | 172.00M |
| Insulet Corp. | 270.80M |
| Marker Therapeutics, Inc. | 14.74M |
| CapsoVision, Inc. | 17.11M |